Sagent Pharmaceuticals Plans Launch of Piperacillin and Tazobactam, the Generic Form of Zosyn(R), for Injection

Sagent Pharmaceuticals, Inc. announced its planned launch of piperacillin and tazobactam for injection, the generic form of Zosyn®, in three distinct single dose vial forms. Piperacillin and tazobactam is used for the treatment of patients with moderate to severe bacterial infections. According to IMS data, the U.S. market for injectable piperacillin and tazobactam approximated $749 million. 
Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent said, Our introduction of generic Zosyn® will add a very significant anti-infective to our rapidly expanding product portfolio. Our piperacillin and tazobactam vials will provide another important source of this frequently prescribed antibiotic to the medical community. Piperacillin and tazobactam is widely used in hospital settings because of its efficacy against a broad range of bacteria. Our product also includes the benefits of our PreventIV Measures™ packaging and labeling, designed to aid in the reduction of medication errors.

About Piperacillin and Tazobactam for Injection

Piperacillin and tazobactam is indicated for the treatment of patients with moderate to severe infections caused by piperacillin-resistant, piperacillin and tazobactam susceptible, beta-lactamase producing strains of the designated microorganisms in a number of conditions such as: appendicitis (complicated by rupture or abscess), peritonitis, uncomplicated and complicated skin and skin structure infections, postpartum endometritis or pelvic inflammatory disease, community-acquired pneumonia (moderate severity only) and nosocomial pneumonia (moderate to severe). Please see DOSAGE and ADMINISTRATION for complete details.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products.  Sagent operates a global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, which quickly yields an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients.